Vardenafil for the treatment of erectile dysfunction in men with diabetes / 中华男科学杂志
National Journal of Andrology
;
(12): 794-797, 2004.
Article
in Chinese
| WPRIM
| ID: wpr-267811
ABSTRACT
The prevalence of erectile dysfunction (ED) is higher in diabete patients than in non-diabete men. Moreover, the treatment of ED is more challenging in men with diabetes. Vardenafil, a novel and highly selective phosphodiesterase 5 inhibitor, is the first line therapy for the broad ED population. Recent large-scale clinical trials indicated that vardenafil improved erectile function in ED men with diabetes regardless of the baseline ED severity and plasma HbA1c levels, and it was generally well tolerated.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phosphodiesterase Inhibitors
/
Piperazines
/
Sulfones
/
Triazines
/
Surveys and Questionnaires
/
Treatment Outcome
/
Therapeutic Uses
/
Diabetes Complications
/
Drug Therapy
/
Vardenafil Dihydrochloride
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2004
Type:
Article
Similar
MEDLINE
...
LILACS
LIS